[The effect of adreno- and sympathoblocking substances on ophthalmotonus (review of the literature)].
D000433:1-Propanol / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001593:Benzyl Compounds / Q000494:pharmacology; D001949:Bretylium Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D002746:Chlorpromazine / Q000494:pharmacology / Q000627:therapeutic use; D003983:Dibenzylchlorethamine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004878:Ergotamine / Q000494:pharmacology / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D006145:Guanethidine / Q000494:pharmacology / Q000627:therapeutic use; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008750:Methyldopa / Q000494:pharmacology / Q000627:therapeutic use; D010646:Phentolamine / Q000008:administration & dosage; D010647:Phenyl Ethers / Q000494:pharmacology; D011299:Prenylamine / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use; D011817:Rabbits
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001593:Benzyl Compounds; D001949:Bretylium Compounds; D006146:Guanidines; D010647:Phenyl Ethers; D000644:Quaternary Ammonium Compounds; D003983:Dibenzylchlorethamine; D008750:Methyldopa; D000433:1-Propanol; D011299:Prenylamine; D004878:Ergotamine; D002746:Chlorpromazine; D010646:Phentolamine; D006145:Guanethidine
Vliianie adreno- i simpatoblokiruiushchikh veshchestv na oftal'motonus (review of the literature.